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ABSTRACT - Purpose. Adenosine plays an important role in the pathogenesis of homocysteine-associated 
vascular complications. Methods: This study examined the effects of dipyridamole, an inhibitor for nucleoside 
transport, on impaired angiogenic processes caused by homocysteine and adenosine in human cardiovascular 
endothelial cell line (EAhy926). Results: The results showed that dipyridamole restored the extracellular 
adenosine and intracellular S-adenosylhomocysteine concentrations disrupted by the combination of 
homocysteine and adenosine. Dipyridamole also ameliorated the impaired proliferation, migration and 
formation of capillary-like tubes of EAhy926 cells caused by the combination of homocysteine and adenosine. 
Mechanism analysis revealed that dipyridamole induced the phosphorylation of mitogen-activated protein 
kinase kinase (MEK) and extracellular signal-regulated kinases (ERK) and its effect on cell growth was 
attenuated by the MEK inhibitor, U0126. Conclusion: Dipyridamole protected against impaired angiogenesis 
caused by homocysteine and adenosine, at least in part, by activating the MEK/ERK signalling pathway, and 
this could be associated with its effects in suppressing intracellular S-adenosylhomocysteine accumulation. 
Novelty of the Work: This is the first paper showing that nucleoside transport inhibition by dipyridamole 
reduced impaired angiogenic process caused by homocysteine and adenosine.  
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may 
comment by clicking on ABSTRACT on the issue’s contents page. 
  
 
INTRODUCTION 
 
Blood vessels form a tubular network to facilitate 
blood transportations in the circulatory system, and 
assist distant exchanges of oxygen, carbon dioxide, 
wastes, electrolytes and hormones from one part of 
the body to the other. Angiogenesis, defined as the 
formation of new vessels from existing vasculature, 
is an essential physiological process for maintaining 
tissue homeostasis by facilitating nutrient 
transportation, as well as promoting tissue growth 
and repair (1). Insufficient angiogenesis can 
complicate conditions such as myocardial infarction 
and ischaemic stroke, which are associated with 
inadequate blood supply (1). Therefore, promoting 
angiogenesis may be a therapeutic approach for 
improving the outcome of ischaemic cardiovascular 
and cerebrovascular diseases. 
 Homocysteine is a sulfur-containing amino 
acid derived from methionine metabolism. An 
accumulation of plasma homocysteine, often 
referred to as hyperhomocysteinaemia, has been 
suggested as an independent predictor for ischaemic 
heart diseases and stroke (2). Hence, 
hyperhomocysteinaemia is an emerging risk factor 
for cardiovascular diseases as indicated by the 
World Health Organization (3). Several reports 
have highlighted the importance of adenosine in the 
pathogenesis of vascular complications associated 
with hyperhomocysteinaemia, where its 
extracellular level is increased in response to cell 
injury and stress, such as in ischaemia (4-6). 
Animal and cellular studies have shown that the 
combination   of   homocysteine   and   adenosine  
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sensitised tumour necrosis factor (TNF) 
cytotoxicity and apoptosis in endothelial cells, as 
well as impaired angiogenesis (7-9). In particular, 
the anti-angiogenic effects of homocysteine and 
adenosine can be associated with inhibiting 
extracellular signal-regulated kinases (ERK) and 
protein kinase B (Akt) signalling pathway (9). Both 
homocysteine and adenosine are key intermediates 
involved in the methionine cycle which regulates 
cellular methylation (10). In the methionine cycle, 
methylation of DNA, RNA, proteins, phospholipids 
and other small molecules occurs when S-
adenosylmethionine is demethylated to S-
adenosylhomocysteine by methyltransferases. S-
adenosylhomocysteine is subsequently hydrolysed 
to homocysteine and adenosine by S-
adenosylhomocysteine hydrolase (10). However, 
when the basal levels of homocysteine and 
adenosine are high, this favours the accumulation of 
S-adenosylhomocysteine by reversing the hydrolase 
reactions of S-adenosylhomocysteine hydrolase. S-
adenosylhomocysteine is known to inhibit 
methyltransferase activities, therefore, the 
accumulation of S-adenosylhomocysteine can 
inhibit methyl transfer reactions resulting in cellular 
hypomethylation (11). 
 Up till now, there is no recognised treatment 
regimens for the management of cardiovascular 
events associated with hyperhomocysteinaemia 
(12). Understanding the connections between 
homocysteine and adenosine in the methionine 
cycle may shed light for novel therapeutic 
interventions in vascular complications associated 
with hyperhomocysteinaemia. It is known that a 
high level of homocysteine induces the synthesis of 
S-adenosylhomocysteine using the intracellular 
adenosine pool. This creates a transmembranous 
adenosine gradient and subsequently, facilitates the 
cellular uptake of extracellular adenosine (5,13). 
Dipyridamole is a clinical anti-platelet drug 
approved for the prevention of thromboembolism, 
and secondary prevention of ischaemic stroke and 
transient ischaemic attack. Animal studies have 
shown that dipyridamole reversed peripheral 
ischaemia and induced angiogenesis (14). 
Dipyridamole is known to inhibit the cellular 
uptake of adenosine by blocking cell surface 
nucleoside transporters, such as equilibrium 
nucleoside transporters (ENTs) (15). Considering 
that adenosine is prominent in vascular 
complications associated with homocysteine, there 
is a lack of studies evaluating the potential of 
nucleoside transport inhibitors in retarding the 
cellular uptake of adenosine in 
hyperhomocysteinaemia. Therefore, this study 
examined the protective effects and mode of actions 
of a clinically used nucleoside transport inhibitor, 
dipyridamole, on angiogenesis impairment caused 
by homocysteine and adenosine in human 
cardiovascular endothelial cell line (EAhy926) 
cells. 
 
MATERIALS AND METHODS  
 
Materials  
U0126, phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (D13.14.4E), p44/42 MAPK 
(ERK1/2) (137F5), phospho-MEK1/2 (Ser217/221) 
(41G9) and MEK1/2 (47E6) antibodies were 
purchased from Cell Signalling Technology (USA). 
α-Tubulin (DM1A) was purchased from Santa Cruz 
Biotechnology (USA). CellTiter
®
 96 Aqueous One 
Solution Cell Proliferation Assay kit was purchased 
from Promega (Australia). Cultrex Basement 
Membrane Extract (BME) was purchased from 
Trevigen (USA). Cell culture reagents were from 
Life Technology (Australia). Chemicals, including 
adenosine, dipyridamole, DL-homocysteine, S-
adenosylhomocysteine and theophylline were from 
Sigma-Aldrich (Australia) unless otherwise stated. 
 
Cell line and Culture Conditions 
Human cardiovascular endothelial cell line 
(EAhy926) was kindly provided by Dr Shanhong 
Ling (Monash University Central Clinical School, 
Australia). The cell line was cultured in Dulbecco's 
modification of Eagle's medium (DMEM)/Ham’s 
F12 containing 15 mM HEPES and L-glutamine 
and supplemented with 10% foetal bovine serum, 
100 U/mL of penicillin and streptomycin (Gibco 
BRL, Australia) (7). The cell line was grown in a 
5% CO2 -humidified incubator at 37°C.  
 
Determination of Extracellular Adenosine 
Concentration 
To determine the extracellular adenosine 
concentrations, EAhy926 cells were seeded at a 
density of 1.0 x 10
5
 cells/mL in a 6 well cell culture 
plate and allowed to adhere and become confluent 
for 24 - 48 h. Once confluent, the EAhy926 cells 
were exposed to homocysteine, adenosine and/or 
dipyridamole in serum free medium for 3 h. The 
J Pharm Pharm Sci (www.cspsCanada.org) 18(5) 856 - 866, 2015 
 
 
 
 
858 
cell culture supernatant was collected and filtered 
through a 0.22 μm syringe filter. The analyses were 
performed using a Waters Acquity ultra 
performance liquid chromatography (UPLC) H 
series consisting of a H class quaternary solvent 
manager, an Acquity sample manager-FTN, an 
Acquity column oven and an Acquity Photodiode 
Array detector, scanning from 190 – 400 nm, and 
the detection wavelength was set at 254 nm 
(Waters, MA, USA). Separation was carried out 
using a Waters BEH C18 column (1.7 μm, 2.1 mm 
x 150 mm) coupled with a BEH guard column (1.7 
μm, 2.1 mm x 5 mm) maintained at 40oC. A binary 
gradient elution method at a flow rate of 0.3 mL 
min
-1
 was employed using (A) 0.3% glacial acetic 
acid and (B) acetonitrile starting from 0.5% B to 
3% B in 3 mins, then to 20% B in 20 mins, back to 
initial 0.5% B in 3 mins. The system was then re-
equilibrated at the initial conditions for 5 mins. The 
total run time was 15 min. All injection volumes of 
samples and authentic standards were 1 μL. The 
identification of adenosine in the supernatant was 
based on the authentic standards. Retention time 
and absorbance spectra were used to confirm the 
presence of adenosine. Quantitative estimations of 
adenosine were based on calibration curves 
generated by UPLC-PDA using the adenosine 
standard. The linear range of the calibration curve 
used for quantification was 50 - 1000 μM. 
 
Determination of Intracellular S-
Adenosylhomocysteine Concentration 
To determine the intracellular S-
adenosylhomocysteine concentration, EAhy926 
cells were seeded at a density of 1.0 x 10
5
 cells/mL 
in a T75 flask and allowed to adhere and become 
confluent for 24-48 h. Once confluent, the 
EAhy926 cells were exposed to homocysteine, 
adenosine and/or dipyridamole in serum-free 
medium for 3 h. The cells were harvested and 
washed once with PBS. The cells were then lysed 
by 100 μL of 10% perchloric acid for 30 mins on 
ice using sonication. The supernatant was collected 
by centrifugation at 20,500 x g for 10 mins at 4
o
C. 
After filtration by a 0.22 μm centrifuge tube filter, 
the supernatant was collected and injected into a 
Waters Acquity UPLC system
®
, while the pellet 
was collected and dissolved in 2M NaOH for 
protein quantification using the Bradford reagent. 
The separation of supernatant was carried out using 
a Waters BEH C18 column (1.7 μm, 2.1 mm x 150 
mm) coupled with a BEH guard column (1.7 μm, 
2.1 mm x 5 mm) maintained at 40
o
C. A binary 
gradient elution method at a flow rate of 0.3 mL 
min
-1
 was employed using (A) 5 mM pentasulfonic 
acid in 0.1% phosphoric acid and (B) acetonitrile, 
starting from 5% B to 20% B in 7 mins, then to 
80% B in 3 mins, back to initial 5% B in 5 mins. 
The system was re-equilibrated at the initial 
conditions for 5 mins. The total run time was 20 
min. All injection volumes of samples and authentic 
standards were 1 μL, and the detection wavelength 
was set at 254 nm, scanning from 190 – 400 nm. 
The identification of S-adenosylhomocysteine was 
based on the authentic standards. Retention time 
and absorbance spectra were used to confirm the 
presence of S-adenosylhomocysteine in the cell 
extract. The quantitative estimations of S-
adenosylhomocysteine were based on calibration 
curves generated by UPLC-PDA using S-
adenosylhomocysteine standard. The linear range of 
the calibration curve used for quantification was 1 - 
250 μM. 
 
Cell Growth Determination 
Cell growth was determined using crystal violet 
staining and a commercial MTS kit (CellTiter
®
 96 
Aqueous One Solution Cell Proliferation Assay) as 
per manufacturer instructions. Briefly, 1.0 x 10
4
 
EAhy926 cells per well were seeded in a 96 well 
plate for 2 h and then treated with DL-
homocysteine (DL-Hcy), adenosine (Ado) and/or 
dipyridamole (final DMSO concentration 0.1%) in 
serum free medium. Crystal violet staining was 
performed as previously described with slight 
modifications (16). After the incubation period, the 
wells were fixed with 3% buffered 
paraformaldehyde for 20 minutes. The cells were 
then stained with 0.2% crystal violet in 20% 
methanol for 5 minutes. The excess crystal violet 
stain was rinsed 4 - 5 times with distilled water and 
air-dried. Glacial acetic acid (33%) in Milli-Q water 
was added to extract the crystal violet stain. The 
absorbance was measured at 595 nm. For the MTS 
assay, MTS solution was added and incubated for 2 
h at 37°C. The absorbance was measured at 490 
nm. Cell growth was expressed as a percentage 
relative to control. 
 
Scratch Wound Healing Assay 
Scratch wound healing assay was performed as 
previously described with some modifications (17). 
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Briefly, EAhy926 cells were seeded at a density of 
1.0 x 10
5
 cells/mL and allowed to adhere and 
become confluent for 24 - 48 h. Once confluent, the 
EAhy926 cell monolayer was scratched using a 
1000 μL blue tip, rinsed gently with phosphate-
buffered saline (PBS) and then exposed to 
homocysteine, adenosine and/or dipyridamole in 
serum free medium. After 24 h of incubation, the 
wound was photographed using an inverted phase-
contrast light microscope. The percentages of cell-
free area were analysed using TScratch software 
(18). 
 
Tube Formation Assay 
Tube formation assay was performed as previously 
described with slight modifications (19). Briefly, 50 
μL Cultrex® Basement Membrane Extract (BME) 
per well was used to coat a 96 well flat bottom 
plate. EAhy926 cells (7.5 x 10
3
) were seeded in 
each well and incubated for 2 h and then treated 
with homocysteine, adenosine and/or dipyridamole 
in serum free medium. After 24 h of incubation, the 
well was photographed using an inverted phase-
contrast light microscope. The total number of 
junctions (consisting of at least three branches) per 
field was quantified using a plug-in, Angiogenesis 
Analyzer, developed by Gilles Carpentier in NIH 
Image-J software (National Institutes of Health, 
Bethesda, MD). 
 
Western Blot Analysis 
EAhy926 cells were seeded at a density of 1.0 x 10
5
 
cells/mL in a 60 mm cell culture dish and allowed 
to adhere and become confluent for 24 - 48 h. Once 
confluent, the EAhy926 cells were exposed to 
homocysteine, adenosine and/or dipyridamole in 
serum free medium for 3 h. The cells were 
harvested and washed with ice-cold PBS after 
centrifugation at 500 x g for 5 minutes. The cells 
were then lysed in the commercial 
radioimmunoprecipitation assay lysis buffer system 
(Santa Cruz Biotechnology, USA) on ice with 
frequent agitation for 30 minutes. The cell 
homogenates were centrifuged at 12,000 rpm for 30 
minutes at 4
o
C and the supernatants were collected. 
Protein concentrations were determined using a 
micro BCA
TM
 Kit (Pierce Chemical, USA). Total 
protein (30 µg) mixed with loading buffer was 
denatured at 70
o
C for 15 minutes, 
electrophoretically resolved on iBlot
®
 4 - 12% Bis-
Tris gel (Life Technologies, Australia) and then 
transferred onto a 0.22 µm polyvinylidine difluoride 
(PVDF) membrane (Amersham, USA). The 
membranes were incubated for 1 h at room 
temperature or overnight at 4°C with rabbit primary 
antibody for p-ERK1/2 (1:1000), ERK1/2 (1:1000), 
p-MEK1/2 (1:1000), MEK1/2 (1:1000) or mouse α-
tubulin (1:5000) diluted with 5% bovine serum 
albumin (BSA) in tris-buffered saline with Tween 
20 (TBST). The membrane was then incubated for 
1 h at room temperature with horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse 
secondary antibody (1:2000) (Santa Cruz 
Biotechnology, USA) diluted with 5% BSA in 
TBST. The immune complexes were detected on a 
x-ray film (Fujifilm Corporation, Japan) using 
SuperSignal West Pico chemiluminescent substrate 
(Pierce Chemical, Rockford, IL). For re-probing, 
the membrane was stripped with guanidine 
hydrochloride stripping buffer (6 M guanidine 
hydrochloride, 0.2% Nonidet (NP-40), 0.1 M β-
Mercaptoethanol, 20 mM Tris–HCl, pH 7.5) twice 
for 5 minutes, followed by 5 minutes washing with 
TBST for four times as previously described (20). 
 
Statistical Analyses 
Statistical comparisons were performed using 
GraphPad Version 5.02 (USA). The data was 
analysed by one-way analysis of variance 
(ANOVA) followed by Newman-Keuls post hoc 
test or Student’s t-test for comparing intracellular S-
adenosylhomocysteine levels. Data was expressed 
as mean ± S.E.M. p < 0.05 was considered as 
statistically significant. 
 
RESULTS 
 
Influence of Dipyridamole on Extracellular 
Adenosine and Intracellular S-
adenosylhomocysteine Concentrations  
It is known that high concentrations of 
homocysteine can promote S-
adenosylhomocysteine formation using the 
intracellular adenosine pool and drives the uptake 
of extracellular adenosine (5). Meanwhile, 
dipyridamole is known to inhibit nucleoside 
transporters, such as ENT-1 and ENT-2 (15). 
Therefore, we evaluated the effects of dipyridamole 
on the extracellular adenosine and intracellular S-
adenosylhomocysteine levels following 
homocysteine and adenosine treatment. The results 
demonstrated that homocysteine and adenosine 
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reduced the extracellular adenosine level from 500 
μM to 178 ± 5.52 μM (Fig 1A) with a concomitant 
increase in intracellular S-adenosylhomocysteine 
level to 1.19 ± 0.94 μM/ mg protein (Fig 1B). More 
importantly, simultaneous treatment with 
dipyridamole significantly prevented the depleted 
level of extracellular adenosine (p < 0.05) caused 
by homocysteine and adenosine, and in parallel, 
significantly reduced the increased intracellular S-
adenosylhomocysteine level to 0.10 ± 0.06 μM/ mg 
protein (p < 0.05). 
 
 
 
 
 
Figure 1.  Effects of dipyridamole on extracellular adenosine and intracellular S-adenosylhomocysteine levels in 
EAhy926 cells treated with DL-Hcy and Ado.  EAhy926 cells were exposed to homocysteine (DL-Hcy), adenosine (Ado) 
and dipyridamole for 3 h in serum free medium. UPLC-PDA was employed to study the (A) extracellular adenosine level 
and (B) intracellular S-adenosylhomocysteine (SAH) level in EAhy926 cells following treatment. UPLC-PDA 
chromatograms of (i) authentic standards of adenosine (peak 1) and S-adenosylhomocysteine (peak 2), (ii) control group, 
(ii) DL-Hcy plus Ado, (iii) dipyridamole (0.1 μM) and (iv) dipyridamole (0.5 μM). All results were expressed as mean ± 
S.E.M. in triplicate (n=3). ND refers to not detected. * p < 0.05 compared to DL-Hcy plus Ado treated-group. 
 
 
Effects of Homocysteine and Adenosine on 
Endothelial Cell Growth 
To study the effects of homocysteine and adenosine 
on angiogenesis, endothelial cell growth was 
examined. Cell growth measured by crystal violet 
staining was performed in EAhy926 cells treated 
with increasing concentrations of homocysteine and 
adenosine for 96 h. As shown in Fig 2A - B, the 
results demonstrated that homocysteine promoted a 
small increment in cell growth at 0.5 mM, whereas 
adenosine (up to 0.5 mM) showed no significant 
influences on cell growth. Interestingly, cell growth 
was significantly attenuated in a concentration-
dependent manner when treated with both 
homocysteine and adenosine (0.1 - 0.5 mM) (Fig 
2C). The results showed that the inhibition in 
EAhy926 cell growth caused by homocysteine and 
adenosine was dependent on incubation time and 
reached a plateau after 72 h (Fig 2D). 
 
Influence of Dipyridamole on Impaired 
Endothelial Cell Growth 
To evaluate the effects of dipyridamole on the 
impaired endothelial cell growth caused by 
homocysteine and adenosine, EAhy926 cells were 
treated    with    increasing    concentrations    of  
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Figure 2. Effects of homocysteine and adenosine on endothelial cell growth. Cell growth, as determined by crystal 
violet staining, following treatments with (A) homocysteine (DL-Hcy), (B) adenosine (Ado), and (C) DL-Hcy plus Ado in 
EAhy926 cells for 96 h in serum free medium. (D) Time-dependent effects of DL-Hcy (0.5 mM) plus Ado (0.5 mM) in 
serum free medium on the growth of EAhy926 cells. Cell growth was expressed as fold change relative to control. All 
results were expressed as mean ± S.E.M. in triplicate (n=3). * p < 0.05 compared to control. 
 
 
 
Figure 3. Effects of dipyridamole on impaired endothelial cell growth caused by homocysteine and adenosine. Cell 
growth, as determined by (A) crystal violet staining and (B) CellTiter
®
 96 Aqueous One Solution Cell Proliferation MTS 
assay, following treatments with homocysteine (DL-Hcy), adenosine (Ado) and dipyridamole for 24, 48, 72 and 96 h in 
serum free medium. All results were expressed as mean ± S.E.M. in triplicate (n=3). # p < 0.05 compared to control. * p < 
0.05 compared to DL-Hcy plus Ado treated-group. 
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dipyridamole (0.1 - 0.75 μM) together with 
homocysteine and adenosine for 24, 48, 72 and 96 
h. The results from crystal violet staining showed 
that dipyridamole concentration-dependently 
increased the growth of EAhy926 cells caused by 
homocysteine and adenosine (Fig. 3A).  Similar 
results were also observed using MTS assay 
indicating that dipyridamole improved the growth 
of EAhy926 cells which were inhibited by 
homocysteine and adenosine (Fig 3B). To 
investigate the involvement of adenosine receptor in 
the protective effects of dipyridamole, EAhy926 
cells were incubated with theophylline (non-
selective adenosine receptor antagonist), 
dipyridamole, homocysteine and adenosine for 48 
h. It was found that the addition of adenosine 
receptor antagonist, theophylline, did not inhibit the 
protective effects of dipyridamole on impaired cell 
growth caused by homocysteine and adenosine 
(Fig 4). 
 
 
 
 
Figure 4. Theophylline did not affect the effects of 
dipyridamole on impaired endothelial cell growth 
caused by homocysteine and adenosine. Effects of 
theophylline (a non-selective adenosine receptor 
antagonist) on EAhy926 cell growth affected by DL-Hcy 
and Ado treatment for 48 h using crystal violet staining. 
All results were expressed as mean ± S.E.M. in triplicate 
(n=3). # p < 0.05 compared to control. * p < 0.05 
compared to DL-Hcy plus Ado treated-group. 
 
 
Influence of Dipyridamole on Impaired 
Endothelial Cell Migration and Tube Formation 
Scratch wound healing assay was performed to 
demonstrate the migratory potential of EAhy926 
cells following treatment with homocysteine, 
adenosine and dipyridamole. As shown in Fig 5A, 
treatment with homocysteine and adenosine 
significantly attenuated the percentage of scratch 
wound closure in 24 h, which was subsequently 
improved with dipyridamole treatment (p < 0.05). 
To model the reendothelisation stage of 
angiogenesis in vitro, tube formation assay was 
performed. The results showed that homocysteine 
and adenosine significantly reduced the total 
number of junctions per field in EAhy926 cells 
grown on basement membrane extract compared to 
the control (p < 0.05), indicating the inhibition of 
tube formation (Fig 5B). When the EAhy926 cells 
were treated simultaneously with dipyridamole, the 
inhibited tube formation caused by homocysteine 
and adenosine was significantly restored (p < 0.05). 
 
Influence of Dipyridamole on the 
Phosphorylation of MEK and ERK 
Previous studies have shown that extracellular 
adenosine and intracellular S-
adenosylhomocysteine levels affect the activation 
of the MEK/ERK signalling pathway (21,22). The 
results from immunoblot showed that treatment 
with homocysteine and adenosine reduced the 
expressions of p-MEK1/2 and p-ERK1/2 (Fig 6A). 
Interestingly, when the EAhy926 cells were treated 
simultaneously with dipyridamole, homocysteine 
and adenosine, the depleted expressions of p-
MEK1/2 and p-ERK1/2 were reversed. U0126 
(MEK specific inhibitor) was found to significantly 
diminish the protective effects of dipyridamole 
against depleted cell growth induced by 
homocysteine and adenosine (Fig 6B). 
 
DISCUSSION 
 
Hyperhomocysteinaemia is an independent factor 
for the risk of cardiovascular diseases which can 
lead to defective angiogenesis (2,23). Many 
publications have focused on the vasotoxic effects 
of homocysteine, however the exact 
pathophysiological mechanisms is still unclear (5). 
More recently, studies have revealed that S-
adenosylhomocysteine is a more sensitive indicator 
for the risk of cardiovascular diseases than 
homocysteine (24). In fact, S-
adenosylhomocysteine is a metabolic product from 
homocysteine and adenosine generated by the 
reverse reactions of S-adenosylhomocysteine 
hydrolase. Therefore, adenosine has been linked to 
the pathogenesis of vascular complications 
implicating   hyperhomocysteinaemia  (5),  and  the  
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Figure 5. Effects of dipyridamole on impaired wound healing and tube formations in EAhy926 cells induced by 
homocysteine and adenosine. Wound healing and tube formations were analysed in EAhy926 cells which were exposed to 
homocysteine (DL-Hcy), adenosine (Ado) and dipyridamole for 24 h in serum free medium. (A) The results from scratch 
wound healing assay were presented as the percentage of scratch wound closure in 24 h. (B) The results from tube 
formation assay were presented as the total number of junctions (consisting of at least three branches) per field. All results 
were expressed as mean ± S.E.M. (n=3). # p < 0.05 compared to control. * p < 0.05 compared to DL-Hcy plus Ado treated-
group. 
 
 
 
 
Figure 6. Effects of dipyridamole on the activation of MEK/ERK signalling pathway in EAhy926 cells treated with 
homocysteine and adenosine. EAhy926 cells which were exposed to homocysteine (DL-Hcy), adenosine (Ado) and 
dipyridamole for 3 h in serum free medium. (A) Representative western blot analysis on the phosphorylated MEK1/2 (p-
MEK1/2), total MEK (MEK1/2), phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 (ERK1/2) expressions in 
EAhy926 cells. (B) Effects of U0126 (a MEK specific inhibitor) on EAhy926 cell growth affected by DL-Hcy and Ado. 
EAhy926 cells were exposed to DL-Hcy, Ado, dipyridamole and U0126 for 48 h in serum free medium. Cell growth was 
analysed by crystal violet staining. All results were expressed as mean ± S.E.M. in triplicate (n=3). # p < 0.05 compared to 
control. * p < 0.05 compared to DL-Hcy plus Ado treated-group. ^ p < 0.05 compared to dipyridamole treated-group. 
 
 
combination of homocysteine and adenosine has 
been reported to impair angiogenesis in cellular and 
zebrafish models (9). Our previous reports have 
demonstrated that the combination of homocysteine 
and adenosine exacerbated TNF cytotoxicity and 
apoptosis in endothelial cells (7,8). This connection 
between homocysteine and adenosine has been 
associated with their active involvements in 
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methionine metabolism and cellular methylation, as 
well as the enhanced cellular uptake of adenosine 
induced by homocysteine (13). To the best of our 
knowledge, there is a lack of studies evaluating the 
potential use of nucleoside transport inhibitors to 
block cellular adenosine uptake in vascular 
complications associated with homocysteine. In the 
present study, we show for the first time that a 
clinically used nucleoside transport inhibitor, 
dipyridamole, blocked the impairment in 
angiogenic processes caused by homocysteine and 
adenosine through the activation of the MEK/ERK 
signalling pathway.  
 Accumulating evidence has suggested that 
therapeutic angiogenesis can re-vascularise 
ischaemic tissues to improve nutrient perfusion 
under pathological situations (25). This could 
potentially alleviate the occurrence and severity of 
ischaemic symptoms, and ultimately improve 
functional recovery following ischaemic attacks, 
including myocardial infarction and stroke (26,27). 
Angiogenesis is often studied in vitro using 
vascular endothelial cells focussing on cell growth, 
migration and capillary-like tube formation (28). 
Similar to previous findings, our results 
demonstrated that endothelial cell growth, 
migration and tube formation were compromised 
following treatment with homocysteine and 
adenosine (9). With the addition of dipyridamole, 
these impaired angiogenic processes, caused by the 
combination of homocysteine and adenosine, were 
significantly improved. 
 The mitogen-activated protein kinase 
(MAPK) cascade is an important intracellular signal 
transduction pathway involved in many cellular 
processes, such as cell growth, differentiation, 
motility and survival (29). The MAPK cascade is 
controlled by a sequential protein phosphorylation 
of three main protein kinases i.e. MAPK kinase 
kinase (MAPKKK), MAPK kinase (MAPKK) and 
MAPK (30). ERK1/2, c-Jun amino-terminal kinases 
(JNK), p38 kinases and ERK5 are among the four 
well-characterised mammalian MAPK (30). In 
particular, the activation of Raf/MEK/ERK pathway 
has been highlighted to play an important role in the 
process of angiogenesis (31). In the ERK pathway, 
Raf kinases are the MAPKKK component that 
phosphorylate the MAPKK components MEK1/2 
(30). This, in turn, phosphorylates and activates the 
MAPK component ERK1/2 which are responsible 
for stimulating many downstream effector proteins 
(30). In this study, our results showed that the 
combined incubation of homocysteine and 
adenosine inhibited MEK/ERK signalling pathway 
which agrees with previous reports (9). Based on 
this observation, we studied the effects of 
dipyridamole on the MEK/ERK pathway by using 
immunoblot and a specific MEK inhibitor (U0126). 
We demonstrated that dipyridamole activated the 
homocysteine and adenosine-impaired MEK/ERK 
signalling pathway. Using the specific MEK 
inhibitor, we showed that the proliferative effects of 
dipyridamole in the EAhy926 cells were hindered. 
Thus, the activation of the MEK/ERK signalling 
pathway is, at least in part, involved in the 
angiogeneic effect of dipyridamole.  
 Previous studies have showed that 
homocysteine attenuated ischaemia-induced 
extracellular adenosine accumulation, and this 
could interfere with the vasoactive response of 
adenosine (6). Dipyridamole is known as an 
inhibitor for the cellular uptake of adenosine, and 
has been shown to preserve the vasodilative effects 
of adenosine in patients with 
hyperhomocysteinaemia (13,15). Therefore, the 
effects of dipyridamole in enhancing angiogenesis 
and activating MEK/ERK signalling pathway could 
also be related to its abilities in regulating 
extracellular adenosine and intracellular S-
adenosylhomocysteine concentrations. These 
biochemical alterations may provide an explanation 
for the impaired angiogenesis induced by 
homocysteine and adenosine. The accumulation of 
intracellular S-adenosylhomocysteine has been 
previously reported to diminish the proliferative 
ability of endothelial cells (32), whereas 
extracellular adenosine can induce adenosine 
receptor activation, stimulate vascular endothelial 
growth factor expressions and promote 
angiogenesis (33,34). In terms of MEK/ERK 
signalling pathway, the effects of extracellular 
adenosine and intracellular S-
adenosylhomocysteine concentrations on its 
activations have been previously reported. 
Intracellular S-adenosylhomocysteine accumulation 
inhibited the activities of isoprenylcysteine 
carboxyl methyltransferase and repressed the 
carboxyl methylation of Ras and its membrane 
translocation, leading to the inhibition of the c-
Raf/MEK/ERK signalling pathway (21). 
Meanwhile, the increase in extracellular adenosine 
concentration could lead to adenosine receptor 
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activation. Previous reports have demonstrated that 
adenosine receptors are coupled to MAPK 
signalling pathways, thereby the activation of the 
adenosine receptor can induce the phosphorylation 
and activation of MEK and ERK (22). In the 
present study, dipyridamole increased extracellular 
adenosine and lowered intracellular S-
adenosylhomocysteine levels in EAhy926 cells. 
However, the protective effects of dipyridamole on 
impaired endothelial cell growth were not 
counteracted by theophylline, which is a non-
selective adenosine receptor antagonist. The results 
suggested that the angiogeneic effects of 
dipyridamole may be less associated with adenosine 
receptor activation as a result of extracellular 
adenosine accumulation. For these reasons, we 
speculated that the angiogeneic effects and 
activation of the MEK/ERK signalling pathway 
could be explained by the effects of dipyridamole in 
suppressing intracellular S-adenosylhomocysteine 
accumulation.  
 In summary, the nucleoside transport 
inhibitor, dipyridamole prevented impairment of 
angiogenic processes caused by homocysteine and 
adenosine, at least in part, by activating the 
MEK/ERK signalling pathway. This can be 
associated with the effects of dipyridamole in 
suppressing intracellular S-adenosylhomocysteine 
accumulation. These findings support dipyridamole 
as a potential therapeutic candidate for 
homocysteine-associated vascular complications in 
addition to its clinically proven anti-platelet 
property. 
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